Claims
- 1. A method for treating intracellular infections within warm-blooded animals, comprising:
(a) administering to a warm-blooded animal a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen; and (b) administering to said warm-blooded animal a protein which comprises said immunogenic portion of said antigen, such that an immune response is generated.
- 2. The method according to claim 1, further comprising the step of administering an immunomodulatory cofactor.
- 3. The method according to claim 1 wherein said protein is administered prior to administration of said vector construct.
- 4. The method according to claim 1 wherein said intracellular pathogen is a virus, and said antigen a viral antigen.
- 5. The method according to claim 3 wherein said viral antigen is obtained from a virus selected from the group consisting of hepatitis, feline immunodeficiency virus, and HIV.
- 6. The method according to claim 5 wherein said antigen is a hepatitis B antigen.
- 7. The method according to claim 6 wherein said hepatitis B antigen is selected from the group consisting of HBeAg, HBcAg and HBsAg.
- 8. The method according to claim 5 wherein said antigen is a hepatitis C antigen.
- 9. The method according to claim 8 wherein said hepatitis C antigen is selected from the group consisting of core antigen C, E1, E2/NS1, NS2, NS3, NS4 and NS5.
- 10. The method according to claim 1 wherein said intracellular pathogen is a parasite.
- 11. The method according to claim 1 wherein said vector construct is carried by a recombinant retrovirus.
- 12. The method according to claim 1 wherein said vector construct is carried by a recombinant virus selected from the group consisting of alphaviruses, adeno-associated virus and parvovirus.
- 13. The method according to claim 1 wherein said vector construct is a nucleic acid expression vector, or a eukaryotic layered vector initiation system.
- 14. A composition, comprising a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, a protein which comprises said immunogenic portion of said antigen, and a pharmaceutically acceptable carrier or diluent.
- 15. The composition according to claim 14, further comprising an immunomodulatory cofactor.
- 16. The composition according to claim 14 wherein said intracellular pathogen is a virus, and said antigen a viral antigen.
- 17. The composition according to claim 16 wherein said viral antigen is obtained from a virus selected from the group consisting of hepatitis, feline immunodeficiency virus, and HIV.
- 18. The composition according to claim 16 wherein said antigen is a hepatitis B antigen.
- 19. The composition according to claim 18 wherein said hepatitis B antigen is selected from the group consisting of HBeAg, HBcAg and HBsAg.
- 20. The composition according to claim 16 wherein said antigen is a hepatitis C antigen.
- 21. The composition according to claim 20 wherein said hepatitis C antigen is selected from the group consisting of core antigen C, E1, E2/NS1, NS2, NS3, NS4 and NS5.
- 22. The composition according to claim 14 wherein said intracellular pathogen is a parasite.
- 23. The composition according to claim 1 wherein said vector construct is carried by a recombinant retrovirus.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No. 60/025,267, filed Sep. 17, 1996.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08931031 |
Sep 1997 |
US |
Child |
09466035 |
Dec 1999 |
US |